Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

PURPOSE: In chronic myeloid leukaemia, tyrosine kinase inhibitor treatment is traditionally given continuously for life. However, these drugs produce excellent responses for many patients, and this is accompanied by survival that is close to normal. This has prompted studies of whether it is possibl...

Descripción completa

Detalles Bibliográficos
Autor principal: Clark, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Chronic Myeloid Leukemias (G Saglio, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934633/
https://www.ncbi.nlm.nih.gov/pubmed/31701369
http://dx.doi.org/10.1007/s11899-019-00548-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934633/
https://www.ncbi.nlm.nih.gov/pubmed/31701369
http://dx.doi.org/10.1007/s11899-019-00548-2

Ejemplares similares